# Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

> **NCT01546415** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Iron Overload

## Interventions

- **DRUG:** Desferasirox

## Key facts

- **NCT ID:** NCT01546415
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01546415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01546415, "Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01546415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*